| 6.6 -0.01 (-0.15%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.82 | 1-year : | 9.14 |
| Resists | First : | 6.69 | Second : | 7.82 |
| Pivot price | 6.35 |
|||
| Supports | First : | 6.26 | Second : | 6 |
| MAs | MA(5) : | 6.46 |
MA(20) : | 6.4 |
| MA(100) : | 6.1 |
MA(250) : | 6.13 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 87 |
D(3) : | 70.4 |
| RSI | RSI(14): 56.8  |
|||
| 52-week | High : | 7.59 | Low : | 4.51 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ICCC ] has closed below upper band by 17.5%. Bollinger Bands are 32% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.61 - 6.65 | 6.65 - 6.67 |
| Low: | 6.43 - 6.47 | 6.47 - 6.49 |
| Close: | 6.54 - 6.6 | 6.6 - 6.65 |
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Sun, 05 Apr 2026
Price-Driven Insight from (ICCC) for Rule-Based Strategy - Stock Traders Daily
Thu, 02 Apr 2026
ICCC SEC Filings - Immucell 10-K, 10-Q, 8-K Forms - Stock Titan
Wed, 01 Apr 2026
IMMUCELL (ICCC) director Kathy V. Turner files initial insider Form 3 - Stock Titan
Wed, 25 Mar 2026
(ICCC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Thu, 19 Mar 2026
ImmuCell Corporation (NASDAQ:ICCC) Q1 2025 Earnings Call Transcript - MSN
Wed, 18 Mar 2026
ImmuCell appoints Kathy Turner to board of directors - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 32 (%) |
| Held by Institutions | 20.2 (%) |
| Shares Short | 27 (K) |
| Shares Short P.Month | 18 (K) |
| EPS | -0.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.28 |
| Profit Margin | -3.8 % |
| Operating Margin | -0.8 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | -3.7 % |
| Qtrly Rev. Growth | -1.7 % |
| Gross Profit (p.s.) | 1.26 |
| Sales Per Share | 3.05 |
| EBITDA (p.s.) | 0.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -55 |
| PEG Ratio | 0 |
| Price to Book value | 2 |
| Price to Sales | 2.16 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|